Results 61 to 70 of about 5,819 (161)
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 3, March 2026.ABSTRACT Azathioprine (AZA), a widely used immunosuppressant, can induce acute pancreatitis (AP), yet the underlying molecular mechanisms remain unclear. This study employed an integrative multiomics strategy—combining network toxicology, machine learning, Mendelian randomization (MR), and molecular docking—to elucidate the biological basis of AZA ...
Zhijun Xie +4 more
wiley +1 more source
Immunomodulatory therapy in paediatric inflammatory bowel disease
Zdravniški Vestnik, 2013 Immunomodulatory drugs are indispensable in the treatment of children with both Crohn’s disease and ulcerative colitis, especially in maintaining remission.
András Arató
doaj
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2019 Introduction Ras‐related C3 botulinum toxin substrate 1 (Rac1), a member of the Rho‐GTPase family of proteins, could be an Alzheimer's disease (AD) triggering co‐factor due to its effect on both amyloid precursor protein (APP) and tau.
S.Scott Sutton +3 more
doaj +1 more source
United European Gastroenterology Journal, Volume 14, Issue 2, March 2026.ABSTRACT Introduction Since the publication of the first European Society for the Study of Coeliac Disease (ESsCD) guidelines in 2019, substantial advances have been made in understanding the management and complex disease courses of coeliac disease (CeD) in adults.
Abdulbaqi Al‐Toma +20 more
wiley +1 more source
Alimentary Pharmacology &Therapeutics, Volume 63, Issue 6, Page 859-873, March 2026.This illustration summarises our primary findings highlighting the rising incidence of certain extra‐digestive cancers among persons with IBD over the 25‐year study duration (left), and the relative rates of extra‐digestive cancer incidence and mortality among persons with IBD in recent years (2010–2019) compared to their age‐ and sex‐matched controls (
Sanjay K. Murthy +13 more
wiley +1 more source
Immunosuppressants in modern approaches to treatment of inflammatory bowel diseases
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2013 Aim of investigation. To characterize frequency of TPMT gene mutations in patients with inflammatory bowel diseases (IBD) with myelosuppression and to estimate value of these mutations in prognosis of myelosuppression development in patients receiving ...
O. B. Schukina +6 more
doaj
Frontiers in OncologyAcute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, with relapse being a major obstacle to successful treatment. Our understanding of the mechanisms driving chemotherapy resistance and ultimately relapse in leukemia remains ...
Xiaohong Wang +13 more
doaj +1 more source
Impact of NUDT15 polymorphisms on thiopurines-induced myelotoxicity and thiopurines tolerance dose
Oncotarget, 2017 Thiopurines are widely used as anticancer and immunosuppressive agents. However, life-threatening myelotoxicity has been noticed and largely explained by genetic variations, including NUDT15 polymorphisms (e.g., rs116855232). In this study, we conduct a meta-analysis to investigate the impact of rs116855232 on thiopurines-induced myelotoxicity ...
Yin, Dandan +18 more
openaire +3 more sources
Thiopurines Induce Oxidative Stress in T-Lymphocytes: A Proteomic Approach
Mediators of Inflammation, 2015 Thiopurines are extensively used immunosuppressants for the treatment of inflammatory bowel disease (IBD). The polymorphism of thiopurine S-methyltransferase (TPMT) influences thiopurine metabolism and therapy outcome. We used a TPMT knockdown (kd) model
Misbah Misdaq +4 more
doaj +1 more source
Therapeutic Advances in GastroenterologyBackground: Thiopurines are commonly used to treat inflammatory bowel disease but withdrawal due to side effects are common. Thioguanine has been suggested to be better tolerated than conventional thiopurines.
Helena Gensmyr-Singer +2 more
doaj +1 more source